Phenoxybenzamine Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 10 mg, 20 mg
Reference Brands: Dibenzyline (USA/EU)
Category:
Heart Disorder
Phenoxybenzamine Hydrochloride is available in Capsules
and strengths such as 10 mg, 20 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Phenoxybenzamine Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Phenoxybenzamine Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Phenoxybenzamine hydrochloride is a long-acting, non-selective alpha-adrenergic blocker used primarily in the treatment of hypertension, particularly hypertension caused by pheochromocytoma. It has a slower onset of action and a prolonged duration compared with other alpha-blocking agents, making it especially effective for sustained blood pressure control. Phenoxybenzamine is commonly administered prior to surgical intervention in patients with pheochromocytoma to prevent hypertensive crises.
The drug exerts its antihypertensive effect by forming a permanent covalent bond with alpha-adrenergic receptors, thereby preventing the binding of catecholamines such as epinephrine and norepinephrine. This irreversible blockade results in vasodilation of blood vessels, leading to a sustained reduction in vascular resistance and blood pressure. A known pharmacological effect associated with this mechanism is reflex tachycardia.
Phenoxybenzamine was the first alpha-blocker used in the treatment of benign prostatic hyperplasia, although its use for this indication has declined due to unfavorable side effects. It has also been utilized in conditions such as hypoplastic left heart syndrome and complex regional pain syndrome type 1, where its antiadrenergic properties may provide clinical benefit, particularly when initiated early in disease progression.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing